Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bausch Health Companies Inc

5.30
+0.0000
Post-market: 5.300.00000.00%19:59 EDT
Volume:3.18M
Turnover:16.59M
Market Cap:1.96B
PE:-42.40
High:5.34
Open:5.20
Low:5.00
Close:5.30
Loading ...

Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts?

Insider Monkey
·
22 Apr

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Dow Jones
·
22 Apr

Raymond James Sticks to Its Hold Rating for Bausch Health Companies (BHC)

TIPRANKS
·
22 Apr

BUZZ-Bausch Health says Carl Icahn has economic interest in co, shares rise

Reuters
·
22 Apr

Bausch Health announces filing of supplement to proxy statement

TIPRANKS
·
22 Apr

April 2025's Top Growth Stocks With Strong Insider Ownership

Simply Wall St.
·
22 Apr

Bausch Health Announces Filing of Supplement to Proxy Statement

ACCESS Newswire
·
22 Apr

Bausch Health Companies Inc (BHC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
22 Apr

BofA Cuts Price Target on Bausch Health to $5 From $7

MT Newswires Live
·
21 Apr

Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?

Zacks
·
21 Apr

Bausch says court grants summary judgment in favor of FDA, Salix, and Teva

TIPRANKS
·
18 Apr

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

ACCESS Newswire
·
18 Apr

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

ACCESS Newswire
·
11 Apr

Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?

Zacks
·
10 Apr

Bausch Health Unit Signs LoI for Public Listing of Acne Gel Cabtreo in Canada

MT Newswires Live
·
09 Apr

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

ACCESS Newswire
·
09 Apr

Bausch Health's Q1 Revenue Expected to Narrowly Miss Consensus Estimates, RBC Capital Says

MT Newswires Live
·
08 Apr

RBC Capital Adjusts PT on Bausch Health Companies to $8.50 From $9, Keeps Sector Perform Rating

MT Newswires Live
·
07 Apr

Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment

StockStory
·
07 Apr

Bausch Health Companies Inc : RBC Cuts Target Price to $8.5 From $9

THOMSON REUTERS
·
07 Apr